Cliical Trials: Novel Endpoint Development & Digital Biomarkers

KPIs, Dashboards and Analytics to Measure Novel Endpoint Development & Digital Biomarkers Success KPIs, Dashboards and Analytics to Measure Novel Endpoint Development & Digital Biomarkers Success In recent years, the landscape of clinical trials has transformed significantly, especially with the introduction of novel endpoints and digital biomarkers. This article serves as a comprehensive guide, providing…

Read More “KPIs, Dashboards and Analytics to Measure Novel Endpoint Development & Digital Biomarkers Success” »

Digital Tools, Platforms and Data Lakes to Power Novel Endpoint Development & Digital Biomarkers Digital Tools, Platforms and Data Lakes to Power Novel Endpoint Development & Digital Biomarkers In the rapidly evolving landscape of clinical research, especially for prostate cancer clinical trials, the integration of digital tools and innovative data management strategies plays a pivotal…

Read More “Digital Tools, Platforms and Data Lakes to Power Novel Endpoint Development & Digital Biomarkers” »

Scenario Planning and Portfolio Strategy Anchored in Novel Endpoint Development & Digital Biomarkers The landscape of clinical research is rapidly evolving, particularly with advancements in novel endpoint development and the integration of digital biomarkers. This comprehensive guide outlines a step-by-step approach to scenario planning and portfolio strategy in this newly transforming environment, focusing primarily on…

Read More “Scenario Planning and Portfolio Strategy Anchored in Novel Endpoint Development & Digital Biomarkers” »

Using Real-World Data and RWE to Strengthen Novel Endpoint Development & Digital Biomarkers Decisions Introduction to Real-World Data (RWD) and Real-World Evidence (RWE) Real-World Data (RWD) and Real-World Evidence (RWE) have become integral components of the modern pharmaceutical research and development (R&D) landscape. These concepts provide crucial insights into the efficacy and safety of interventions…

Read More “Using Real-World Data and RWE to Strengthen Novel Endpoint Development & Digital Biomarkers Decisions” »

Talent, Skills and Operating Models Needed to Deliver on Novel Endpoint Development & Digital Biomarkers Talent, Skills and Operating Models Needed to Deliver on Novel Endpoint Development & Digital Biomarkers The evolution of clinical trials, particularly in the context of novel endpoints and digital biomarkers, necessitates a robust framework of talent, skills, and operating models…

Read More “Talent, Skills and Operating Models Needed to Deliver on Novel Endpoint Development & Digital Biomarkers” »

Emerging Science and Technology Trends Redefining Novel Endpoint Development & Digital Biomarkers Emerging Science and Technology Trends Redefining Novel Endpoint Development & Digital Biomarkers As the landscape of clinical research continues to evolve, the integration of novel endpoints and digital biomarkers has become increasingly crucial in enhancing the efficacy and precision of clinical trials. This…

Read More “Emerging Science and Technology Trends Redefining Novel Endpoint Development & Digital Biomarkers” »

Roadmap: 12–24 Month Plan to Upgrade Your Organization’s Novel Endpoint Development & Digital Biomarkers Roadmap: 12–24 Month Plan to Upgrade Your Organization’s Novel Endpoint Development & Digital Biomarkers As the field of clinical research continues to evolve, the need for innovative approaches in endpoint development and the incorporation of digital biomarkers has become paramount. Clinical…

Read More “Roadmap: 12–24 Month Plan to Upgrade Your Organization’s Novel Endpoint Development & Digital Biomarkers” »

Sustainability, ESG and Green R&D Considerations in Novel Endpoint Development & Digital Biomarkers The pharmaceutical industry is at a pivotal juncture where the integration of sustainability, environmental, social, and governance (ESG) principles into research and development is increasingly vital. As this industry evolves, the ability to conduct clinical trials efficiently while adhering to these principles…

Read More “Sustainability, ESG and Green R&D Considerations in Novel Endpoint Development & Digital Biomarkers” »

IP, Exclusivity and Deal-Making Implications of Strong Novel Endpoint Development & Digital Biomarkers IP, Exclusivity and Deal-Making Implications of Strong Novel Endpoint Development & Digital Biomarkers The evolution of pharmaceutical research, especially with the emergence of real-world evidence (RWE) clinical trials, is reshaping the landscape of drug development. Understanding the impact of strong novel endpoints…

Read More “IP, Exclusivity and Deal-Making Implications of Strong Novel Endpoint Development & Digital Biomarkers” »

Risk Management and Stage-Gate Governance for Novel Endpoint Development & Digital Biomarkers The development of novel endpoints and digital biomarkers is crucial in the progressive landscape of clinical research, particularly in the realm of amgen clinical trials. As pharmaceutical companies and researchers innovate, the governance structures and risk management strategies must be robust to ensure…

Read More “Risk Management and Stage-Gate Governance for Novel Endpoint Development & Digital Biomarkers” »